MINI FUTURE LONG - ASTRAZENECA | Real-time Euronext Paris 12:23:51 29/04/2024 BST | ||
| 4.245 EUR | +3.66% |
|
| Current month | +53.37% | ||
| 1 month | +77.27% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 4.245 | +3.66% | 33 |
| 26/04/24 | 4.095 | -1.33% | 96 |
| 25/04/24 | 4.15 | +22.96% | 90 |
| 24/04/24 | 3.375 | +2.74% | 60 |
| 23/04/24 | 3.285 | -0.30% | 72 |
Real-time Euronext Paris
Last update April 29, 2024 at 12:23 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
BNP Paribas
|
| FX0FB | |
| ISIN | NLBNPNL1RHE3 |
| Date issued | 28/03/2022 |
| Strike | 8,506 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.5 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.755 € |
|---|---|
| Lowest since issue | 1.15 € |
| Spread | 0.01 € |
| Spread % | 0.23% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
149.3
USD
Average target price
164.3
USD
Spread / Average Target
+10.02%
- Stock Market
- Certificates
- FX0FB Certificat
